"versionIdentifier","id","rationale","uuid:ID","instanceType"
"2","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","e3caf064-523c-44ea-93ad-204723939cd8","StudyVersion"
